February 09, 2010
Feb. 9 (Bloomberg) -- Biogen Idec Inc., the world’s largest maker of medicines for multiple sclerosis, said fourth-quarter profit jumped 48 percent, helped by higher sales of its fastest- growing drug, Tysabri.
Net income increased to $305.6 million, or $1.06 a share, from $206.7 million, or 70 cents, a year earlier, the Cambridge, Massachusetts-based company said today in a statement. Earnings excluding some expenses beat by 16 cents the average $1.04 estimate of 16 analysts surveyed by Bloomberg.
To read the full story, click here.